Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Ocrelizumab treatment is not associated with an increase in anti-JCV antibody index
Multiple Sclerosis
P15 - Poster Session 15 (12:00 PM-1:00 PM)
9-016
To prospectively assess anti-JCV antibody indices (AI) and their relationship to immunoglobulin levels (IL) in ocrelizumab-treated multiple sclerosis (MS) patients pre/post initiation of therapy.

Treatment with the monoclonal antibodies natalizumab and rituximab is associated with progressive multifocal leukoencephalopathy (PML) caused by the JC polyomavirus (JCV). Concerns for a possible PML risk also exist in MS patients treated with the anti-CD20 monoclonal antibody ocrelizumab given its structural similarity to rituximab. PML risk is frequently assessed with the anti-JCV antibody index as an increased anti-JCV AI as well as JCV-seropositivity are associated with an increased risk for development of PML in natalizumab-treated MS patients.
This is a prospective observational study over 24 months assessing anti-JCV AI and IL in ocrelizumab-treated MS patients enrolled in the institutional ocrelizumab safety data base of the University of Florida. Anti-JCV AI and IL were obtained before and after initiation of ocrelizumab. This data was analyzed to assess for change and correlation between AI and IL after initiation of ocrelizumab.
Ninety-nine ocrelizumab-treated MS patients with an initial pre-treatment anti-JCV AI were followed. No significant change in anti-JCV AI titers and a significant decrease in immunoglobulin M (IgM) were observed after initiation of ocrelizumab treatment. There was a trend towards correlation between differences in anti-JCV AI and IgM.

Treatment with ocrelizumab is not associated with an increase in anti-JCV AI titers as observed in natalizumab therapy. It remains uncertain if the anti-JCV AI adequately reflects PML risk in ocrelizumab-treated patients as changes in anti-JCV AI could represent the medication’s effect on circulating antibodies.
Authors/Disclosures
Torge Rempe, MD (University of Florida College of Medicine - Neurology)
PRESENTER 		Dr. Rempe has nothing to disclose.
Aaron M. Carlson, MD (University of Colorado, School of Medicine, Department of Neurology) Dr. Carlson has received research support from Horizon Therapeutics (Amgen).
Augusto A. Miravalle, MD, FÂ鶹´«Ã½Ó³»­ (Rush University) Dr. Miravalle has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Miravalle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Miravalle has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Miravalle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG. Dr. Miravalle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Miravalle has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Miravalle has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Miravalle has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Miravalle has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for BMS. Dr. Miravalle has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Miravalle has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for TG therapeutics. Dr. Miravalle has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. The institution of Dr. Miravalle has received research support from Genzyme. The institution of Dr. Miravalle has received research support from EMD Serono. The institution of Dr. Miravalle has received research support from Alexion.
Tirisham Gyang, MD (Ohio State Univeristy, Wexner Medical Center, Department of Neurology) Dr. Gyang has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono.